醋酸钠林格液围手术期临床应用专家共识

2018-02-01 中国临床麻醉/疼痛相关专家组(统称) 国际麻醉学与复苏杂志,2018,39(1) :1-5.

液体治疗是指通过补充或限制某些液体以能纠正体液平衡失常或维持体液平衡的治疗方法。目前越来越多的研究证明液体治疗时液体种类和输液量的不同可直接影响患者的水、电解质、酸碱、渗透、凝血功能及肝肾功能状态,从而影响康复过程和预后。临床液体治疗所用的两大类液体为胶体液和晶体液。晶体液输注后仅约20%存留于血管内,80%迅速进入组织间隙,故其主要用于补充功能性ECF容量。临床液体治疗的关键是个体化治疗方案和液

中文标题:

醋酸钠林格液围手术期临床应用专家共识

发布日期:

2018-02-01

简要介绍:

液体治疗是指通过补充或限制某些液体以能纠正体液平衡失常或维持体液平衡的治疗方法。目前越来越多的研究证明液体治疗时液体种类和输液量的不同可直接影响患者的水、电解质、酸碱、渗透、凝血功能及肝肾功能状态,从而影响康复过程和预后。临床液体治疗所用的两大类液体为胶体液和晶体液。晶体液输注后仅约20%存留于血管内,80%迅速进入组织间隙,故其主要用于补充功能性ECF容量。临床液体治疗的关键是个体化治疗方案和液体种类优选,液体制剂的正确选择应基于患者生理需要与病理生理改变,此外,还受临床医师的个人经验和医疗市场所能提供的液体种类等综合因素制约。正确的个体化液体治疗可通过调整ECF,改善患者全身体液的状况,从而加速患者康复,这是临床治疗学的重要组成部分。围手术期液体治疗的目的是避免脱水,维持有效血容量,并防止组织灌注不足。

 

拓展指南:围手术期相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=醋酸钠林格液围手术期临床应用专家共识)] GetToolGuiderByIdResponse(projectId=1, id=359cd1c00155ae7a, title=醋酸钠林格液围手术期临床应用专家共识, enTitle=, guiderFrom=国际麻醉学与复苏杂志,2018,39(1) :1-5., authorId=null, author=, summary=液体治疗是指通过补充或限制某些液体以能纠正体液平衡失常或维持体液平衡的治疗方法。目前越来越多的研究证明液体治疗时液体种类和输液量的不同可直接影响患者的水、电解质、酸碱、渗透、凝血功能及肝肾功能状态,从而影响康复过程和预后。临床液体治疗所用的两大类液体为胶体液和晶体液。晶体液输注后仅约20%存留于血管内,80%迅速进入组织间隙,故其主要用于补充功能性ECF容量。临床液体治疗的关键是个体化治疗方案和液, cover=, journalId=null, articlesId=null, associationId=1264, associationName=中国临床麻醉/疼痛相关专家组(统称), associationIntro=, copyright=0, guiderPublishedTime=Thu Feb 01 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>液体治疗是指通过补充或限制某些液体以能纠正体液平衡失常或维持体液平衡的治疗方法。目前越来越多的研究证明液体治疗时液体种类和输液量的不同可直接影响患者的水、电解质、酸碱、渗透、凝血功能及肝肾功能状态,从而影响康复过程和预后。临床液体治疗所用的两大类液体为胶体液和晶体液。晶体液输注后仅约20%存留于血管内,80%迅速进入组织间隙,故其主要用于补充功能性ECF容量。临床液体治疗的关键是个体化治疗方案和液体种类优选,液体制剂的正确选择应基于患者生理需要与病理生理改变,此外,还受临床医师的个人经验和医疗市场所能提供的液体种类等综合因素制约。正确的个体化液体治疗可通过调整ECF,改善患者全身体液的状况,从而加速患者康复,这是临床治疗学的重要组成部分。围手术期液体治疗的目的是避免脱水,维持有效血容量,并防止组织灌注不足。 </P> <P> </P>拓展指南:<strong>与<font color=red>围手术期</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=0e9341c00155a42d" title="老年患者围手术期管理北京协和医院专家共识" target=_blank>老年患者围手术期管理北京协和医院专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=071ef1c0015a1551" title="围手术期抗风湿病药物使用管理最新指南" target=_blank>围手术期抗风湿病药物使用管理最新指南</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2fcc71c001538aff" title="颅咽管瘤围手术期管理中国专家共识(2017)" target=_blank>颅咽管瘤围手术期管理中国专家共识(2017)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=1a9e91c0015383aa" title="围手术期血糖管理医-药专家共识" target=_blank>围手术期血糖管理医-药专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=413801c00151a8bb" title="慢性阻塞性肺疾病患者非肺部手术麻醉及围手术期管理专家共识" target=_blank>慢性阻塞性肺疾病患者非肺部手术麻醉及围手术期管理专家共识</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%9B%B4%E6%89%8B%E6%9C%AF%E6%9C%9F" target=_blank>有关围手术期更多指南</a></ul>, tagList=[TagDto(tagId=70530, tagName=:), TagDto(tagId=70134, tagName=醋酸钠林格液), TagDto(tagId=800, tagName=围手术期), TagDto(tagId=611, tagName=临床应用)], categoryList=[CategoryDto(categoryId=29, categoryName=麻醉疼痛科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6974, appHits=192, showAppHits=0, pcHits=4768, showPcHits=3203, likes=117, shares=4, comments=4, approvalStatus=1, publishedTime=Tue Feb 13 21:41:03 CST 2018, publishedTimeString=2018-02-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Feb 13 21:41:03 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 13:56:42 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=醋酸钠林格液围手术期临床应用专家共识)])
醋酸钠林格液围手术期临床应用专家共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1052007, encodeId=defc105200ed0, content=文章不错 受教了 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Thu Sep 16 15:34:34 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959150, encodeId=281d95915071, content=学习了谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75675204152, createdName=14746550m46暂无昵称, createdTime=Wed Apr 21 19:52:22 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306685, encodeId=ad0e306685ca, content=学习了.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epOkJT87jCmCUG1yp69vXg9vNZC9PFmxvLZMtmF2d8iasB497HBk4YatlFDiajgr6WlW20CZW3wF0sw/132, createdBy=8b312331023, createdName=大妙小得, createdTime=Tue Apr 17 15:03:14 CST 2018, time=2018-04-17, status=1, ipAttribution=)]
    2021-09-16 H8888888

    文章不错 受教了 谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1052007, encodeId=defc105200ed0, content=文章不错 受教了 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Thu Sep 16 15:34:34 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959150, encodeId=281d95915071, content=学习了谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75675204152, createdName=14746550m46暂无昵称, createdTime=Wed Apr 21 19:52:22 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306685, encodeId=ad0e306685ca, content=学习了.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epOkJT87jCmCUG1yp69vXg9vNZC9PFmxvLZMtmF2d8iasB497HBk4YatlFDiajgr6WlW20CZW3wF0sw/132, createdBy=8b312331023, createdName=大妙小得, createdTime=Tue Apr 17 15:03:14 CST 2018, time=2018-04-17, status=1, ipAttribution=)]
    2021-04-21 14746550m46暂无昵称

    学习了谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1052007, encodeId=defc105200ed0, content=文章不错 受教了 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Thu Sep 16 15:34:34 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959150, encodeId=281d95915071, content=学习了谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75675204152, createdName=14746550m46暂无昵称, createdTime=Wed Apr 21 19:52:22 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306685, encodeId=ad0e306685ca, content=学习了.谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epOkJT87jCmCUG1yp69vXg9vNZC9PFmxvLZMtmF2d8iasB497HBk4YatlFDiajgr6WlW20CZW3wF0sw/132, createdBy=8b312331023, createdName=大妙小得, createdTime=Tue Apr 17 15:03:14 CST 2018, time=2018-04-17, status=1, ipAttribution=)]
    2018-04-17 大妙小得

    学习了.谢谢

    0